↓ Skip to main content

Metastatic Melanoma – A Review of Current and Future Treatment Options

Overview of attention for article published in Acta Dermato-Venereologica, January 2015
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#5 of 976)
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

blogs
1 blog
twitter
54 tweeters
wikipedia
7 Wikipedia pages
googleplus
1 Google+ user

Citations

dimensions_citation
75 Dimensions

Readers on

mendeley
180 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Metastatic Melanoma – A Review of Current and Future Treatment Options
Published in
Acta Dermato-Venereologica, January 2015
DOI 10.2340/00015555-2035
Pubmed ID
Authors

E Maverakis, L Cornelius, G Bowen, T Phan, F Patel, S Fitzmaurice, Y He, B Burrall, C Duong, A Kloxin, H Sultani, R Wilken, S Martinez, F Patel

Abstract

Despite advances in treatment and surveillance, melanoma continues to claim approximately 9,000 lives in the US annually (SEER 2013). The National Comprehensive Cancer Network currently recommends ipilumumab, vemurafenib, dabrafenib, and high-dose IL-2 as first line agents for Stage IV melanoma. Little data exists to guide management of cutaneous and subcutaneous metastases despite the fact that they are relatively common. Existing options include intralesional Bacillus Calmette-Guérin, isolated limb perfusion/infusion, interferon-α, topical imiquimod, cryotherapy, radiation therapy, interferon therapy, and intratumoral interleukin-2 injections. Newly emerging treatments include the anti-programmed cell death 1 receptor agents (nivolumab and pembrolizumab), anti-programmed death-ligand 1 agents, and oncolytic vaccines (talimogene laherparepevec). Available treatments for select sites include adoptive T cell therapies and dendritic cell vaccines. In addition to reviewing the above agents and their mechanisms of action, this review will also focus on combination therapy as these strategies have shown promising results in clinical trials for metastatic melanoma treatment.

Twitter Demographics

The data shown below were collected from the profiles of 54 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 180 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Pakistan 1 <1%
Colombia 1 <1%
Unknown 177 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 40 22%
Student > Ph. D. Student 37 21%
Student > Bachelor 33 18%
Researcher 20 11%
Student > Doctoral Student 15 8%
Other 35 19%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 50 28%
Agricultural and Biological Sciences 46 26%
Medicine and Dentistry 44 24%
Unspecified 10 6%
Immunology and Microbiology 10 6%
Other 20 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 49. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 March 2018.
All research outputs
#309,408
of 12,639,455 outputs
Outputs from Acta Dermato-Venereologica
#5
of 976 outputs
Outputs of similar age
#8,003
of 290,137 outputs
Outputs of similar age from Acta Dermato-Venereologica
#2
of 71 outputs
Altmetric has tracked 12,639,455 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 976 research outputs from this source. They receive a mean Attention Score of 3.5. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,137 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 71 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.